The newly built complex of RRIUM, which will be under CCRUM, the apex government organization for research in Unani Medicine
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
The Group will continue to make proactive investments of its management resources in the life science business
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
Subscribe To Our Newsletter & Stay Updated
